Drug Profile
Research programme: anticancer therapeutics - Genentech/Xenetic Biosciences
Alternative Names: Cancer compound - Genentech/LipoxenLatest Information Update: 11 Apr 2017
Price :
$50
*
At a glance
- Originator Genentech; Lipoxen Technologies
- Developer Genentech; Xenetic Biosciences
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer